emmnn132-5551212

packaging of Gardasil®, Merck's anti-HPV vaccine

a vaccine effective against the virus strains responsible for 70% of cervical cancer cases, or possibly more

As reported on July 6, 2006 by Etopia Medical News in an article entitled, "Human papillomavirus (HPV) vaccine Gardasil® on track for inclusion in Vaccine for Children (VFC) program; CDC spokesperson sees no "wave of public sentiment" against this breakthrough treatment for the prevention of cervical cancer," Merck & Co. has successfully developed and is now providing a vaccine effective against the strains of virus responsible for 70% of cervical cancer cases, as well as two strains of genital warts.

A subsequent Etopia Medical News article, entitled "Dr. Rick Haupt at Merck talks about Gardasil®, a safe and effective vaccine against genital warts and cervical cancer caused by HPV, the human papillomavirus," also published on July 6, 2006, featured a 38-minute audio interview with Dr. Rick Haupt, Executive Medical Director, Policy, Public Health and Medical Affairs, Merck Vaccine Division, talking in depth about this then-new medical breakthrough against "cervical cancer, the second-biggest cancer killer in women worldwide."

It now appears possible, as reported today in an article from Reuters entitled "Merck's Gardasil may give wider cancer protection," that:

"The world's first cervical cancer vaccine may give wider protection against the killer disease than previously thought, researchers said on Sunday.

"New data presented at a medical conference in Prague showed Merck & Co Inc's Gardasil had the potential to neutralise additional strains of the sexually transmitted human papillomavirus (HPV) that causes the disease.

"HPV types 16 and 18, which are directly targeted by Gardasil, are responsible for 75 percent of all cervical cancer. But scientists found the vaccine also induces an antibody response capable of neutralising strains 31 and 45, which together account for another 8 to 9 percent of cases."

In order to provide those who may have missed the lengthy and detailed July 6, 2006, Etopia Medical News audio interview with Dr. Rick Haupt, Executive Medical Director, Policy, Public Health and Medical Affairs, Merck Vaccine Division, about this breakthrough in cancer prevention, that conversation has now been added to the Medical Interviews Channel Brightcove Player which debuted in an August 14, 2006, Etopia Medical News article entitled "Medical Interview Channel launches with conversations about bi-polar research, remote medical presence, and psilocybin research."

You can listen to that interview with Dr. Rick Haupt at Merck, in part or in its entirety, by clicking on the appropriate menu button in the Medical Interviews Channel below.

You can become a Brightcove Affiliate and then syndicate the Brightcove Player containing the Medical Interviews Channel to your own web site by clicking here.

You can also get a link, e-mail a link, or get an RSS Feed to the Medical Interviews Channel Brightcove Player by clicking on the envelope icon immediately to the left of the "Play All" button close to the bottom of the player.

Get into the swing of things with additional Etopia Media News Network articles and interviews and Google Alerts